GlassScriptPhysician profile
Leah Raff
NPI 1356715304
$5,054.84
in general payments reported to CMS, 2019-2025
20 companies · $1,640 in 2025
The $1,640 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $150 · 2022: $1,009 · 2023: $583 · 2024: $1,673 · 2025: $1,640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,300 · Food and Beverage: $1,596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,299.88 |
| Food and Beverage | $1,595.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,874.76 | 2022-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Atricure, INC. | $1,663.30 | 2023-2025 | Synergy Ablation System, Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Janssen Pharmaceuticals, INC | $279.71 | 2022-2023 | Xarelto |
| Novo Nordisk INC | $196.71 | 2021-2023 | Wegovy |
| Impulse Dynamics (USA) INC. | $149.07 | 2023 | Optimizer |
| Merck Sharp & Dohme LLC | $140.28 | 2021-2022 | |
| Pfizer INC. | $128.59 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $112.39 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.93 | 2021-2022 | |
| Esperion Therapeutics, INC. | $84.56 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $53.11 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $50.51 | 2021-2023 | Lifevest |
| Abiomed | $37.02 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.93 | 2023 | |
| Angiodynamics, INC. | $34.71 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $27.91 | 2021-2022 | |
| Amarin Pharma, INC. | $24.66 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $22.07 | 2023 | Opsumit |
| Novartis Pharmaceuticals Corporation | $19.07 | 2022 | |
| Philips North America LLC | $13.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leah Raff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.